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ABSTRACT
The statements produced by the Chairmen and Speakers of the 3rd International Symposium on Diverticular 
Disease, held in Madrid on April 11th-13th 2019, are reported. Topics such as current and evolving concepts 
on the pathogenesis, the course of the disease, the news in diagnosing, hot topics in medical and surgical 
treatments, and finally, critical issues on the disease were reviewed by the Chairmen who proposed 39 
statements graded according to level of evidence and strength of recommendation. Each topic was explored 
focusing on the more relevant clinical questions. The vote was conducted on a 6-point scale and consensus 
was defined a priori as 67% agreement of the participants. The voting group consisted of 124 physicians 
from 18 countries, and agreement with all statements was provided. Comments were added explaining some 
controversial areas.
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INTRODUCTION
Diverticulosis of the colon is the most frequent anatomical 
alteration of the colon in the developed countries, and 
the highest rates occur in the United States and Europe. 
This condition nowadays ranks as fifth most important 
gastrointestinal disease in terms of direct and indirect costs 
[1, 2]. When diverticulosis becomes symptomatic, it is called 
“diverticular disease” (DD), a term generally including 
symptomatic uncomplicated diverticular disease (SUDD) and 
acute diverticulitis (AD) [1, 2]
Although the pathogenesis and management of 
diverticulosis and DD remain uncertain, new hypotheses and 
observations are changing the pharmacological and surgical 
management of DD. 
Recommendations for the diagnosis and treatment of 
DD have been issued by many medical societies in various 
countries. However, these recommendations are often 
conflicting [3, 4], generating uncertainties in the clinician and 
dissatisfaction in patients. 
We have summarised the current perspective on DD in 
this consensus conference report, aiming to develop guidelines 
for the clinical, diagnostic and therapeutic management of 
DD in light of the presentations during the 3rd International 
Symposium on Diverticular Disease, held in Madrid on April 
11th-13th, 2019.
METHODS
The primary aim of this document was to provide 
clinical guidelines for appropriate definition, diagnosis and 
management of diverticulosis and DD according to the opinion 
of the participants to the 3rd International Symposium on 
Diverticular Disease, held in Madrid on April 11-13, 2019. 
The promoters of this initiative were the Chairmen of this 
International Symposium (A.T., F.D.M., G.B., A.L., C.S.). 
This International Symposium on Diverticular Disease was 
constituted by six main sessions (current and evolving concepts 
on the pathogenesis, news on the course of the disease, the 
news in diagnosing, hot topics in medical therapy, hot topics 
in surgical treatments, and finally critical issues on the disease). 
The evidence-based Delphi-like process developed consensus 
statements following proposals by designated speakers. The 
process allowed individual feedback and changes of views 
during the process regulated by the coordinators of each session 
and the Chairmen of the Symposium.
The principal steps in the process were: (a) selection of 
the consensus group; (b) identification of areas of clinical 
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importance; (c) systematic literature reviews by using Medline/
PubMed and the Cochrane Database to identify evidence 
to support each statement, draft statements and discussion 
with the coordinators of each session and the Chairmen of 
the Symposium supported by the evidence specific to each 
statement. The modified statements of the 2nd International 
Symposium [5] were used to define statements of this 
Symposium. Evidence-based discussions with key references 
were provided for each statement, and a two-rounds assessing 
statements was conducted. 
Each recommendation was graded according to the Oxford 
Centre for Evidence-Based Medicine, according to the level 
of evidence (EL) and grade of recommendation (RG) [6]. 
Participants, constituted by multi-disciplinary professionals/
experts such as gastroenterologists, gastrointestinal 
endoscopists, surgeons, pathologists, internists, infectious 
diseases and general practitioners, were asked to vote each 
statement linked to the session at the ending of the same 
session. Chairmen, speakers, and members of the scientific 
board did not take part to vote statements. The agreement/
disagreement level was scored on a six-point Likert scale as 
follows: A+: strongly agree; A:
agree with minor reservations; A-: agree with major 
reservations; D-: disagree with major reservations;
D: disagree with minor reservations; D+: strongly disagree. 
Level of agreement was expressed as percentage of each point 
of the scale. Consensus was defined a priori as agreement by 
at least 67% of respondents.  
The format of the following recommendations comprises 
the question, the statement, its level of evidence and strength of 
recommendation, and the percentage agreement of the global 
consensus group on the final version.
In the present document the statements are accompanied 
by comments made by Chairmen of the Meeting. In some areas 
the evidence level is low, reflecting the lack of randomised trials 
and/or good quality studies. For some topics only the expert 
opinion was considered, where appropriate.
Analysis was performed only assessing participant voting 
all statements.
STATEMENTS
One hundred and twenty-four participants voted all 
statements. They came from 18 countries: 1 from Australia, 5 from 
Bulgaria, 1 from Croatia, 1 from Germany, 1 from Israel, 60 from 
Italy, 3 from Mexico, 1 from The Netherlands, 2 from Poland, 2 
from Portugal, 2 from Romania, 3 from Russia, 1 from Serbia, 2 
from Slovakia, 1 from Slovenia, 3 from Spain, 3 from Tunisia, 1 
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from Hungary, and 2 from United States of America.  One hundred 
and two were gastroenterologists, 15 surgeons, 3 internists, 3 
general pratictioners, and 1 specialist on infectious diseases.
1. Pathogenesis 
1.1 There is no sufficient evidence that fiber intake prevents 
the development of diverticulosis. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 38.71%; A 41.94%; A- 
11.29%; D- 3.23%; D 2.42%; D+ 2.42%.
1.2 Diverticular disease and diverticulitis are more likely 
to develop in individuals with genetic predisposition. [EL: 
1b; GR: A]
Consensus levels of agreement: A+ 41.13%; A 37.10%; A- 
16.94%; D- 1.61%; D 3.23%; D+ 0%.
1.3 The routine clinical use of genetic markers is not 
recommended for the prevention, diagnosis and management 
of diverticular diseases. [EL: 1b; GR: A]
Consensus levels of agreement: A+ 70.16%; A 13.71%; A- 
14.52%; D- 0%; D: 0.81%; D+ 0.81%.
1.4 Neuromuscular dysfunction represents a relevant 
pathogenetic factor in colonic diverticulosis. [EL: 3a; GR: C]
Consensus levels of agreement: A+ 49.19%; A 38.71%; A- 
10.48%; D- 1.61%; D: 0%; D+ 0%.
1.5 Colonic motor and sensory abnormalities may play 
a role in the genesis of abdominal pain in patients with 
colonoscopy symptomatic uncomplicated diverticular disease 
(SUDD). [EL: 4a; GR: C]
Consensus levels of agreement: A+ 39.52%; A 46.77%; A- 
11.29%; D- 1.61%; D: 0%; D+ 0.81%.
1.6 In community subjects and patients attending 
colonoscopy with no prior history of diverticulitis and with 
asymptomatic diverticulosis and no endoscopic inflammation 
it is highly unlikely there will be inflammatory changes in 
biopsy of the intervening colonic mucosa. [EL: 1b; GR: A]
Consensus levels of agreement: A+ 56.45%; A 21.77%; A- 
12.90%; D- 4.03%; D: 4.03%; D+ 0.81%.
1.7 Patients with symptomatic uncomplicated diverticular 
disease (SUDD) may have low-grade inflammatory changes 
at the molecular level and microbiome in the biopsy without 
endoscopic inflammation. [EL 3a; GR: B]
Consensus levels of agreement: A+ 39.52%; A 45.16%; A- 
14.52%; D- 0.81%; D: 0%; D+ 0%.
1.8 A diet high in dietary fiber is associated with a 
decreased risk of diverticulitis. [EL: 2b; GR: D]
Consensus levels of agreement: A+ 52.42%; A 40.32%; A- 
2.42%; D- 3.23%; D: 0%; D+ 1.61%.
1.9 Obesity is associated with an increased risk of 
diverticulitis and diverticular bleeding.  [EL: 2a; GR: D]
Consensus levels of agreement: A+ 67.74%; A 24.19%; A- 
3.23%; D- 2.42%; D: 1.61%; D+ 0.81%.
Comments
These statements point out the new evidences on the 
pathogenesis of diverticulosis and diverticular disease. The 
first three statement point out the role of genetic factors to 
the development of DD and AD  [7-14].  The fourth and fifth 
statements point out the significant role of neuromuscular 
abnormalities in the pathogenesis of diverticulosis and DD 
[15-20]. The sixth and the seventh statement point out that 
diverticulosis is a merely expression of an anatomical alteration 
[21-23], while symptomatic uncomplicated diverticular 
disease (SUDD) may have overt inflammation microscopic 
inflammation even without any endoscopic inflammation [24, 
25]. The last two statements point out the role of high fiber diet 
in reducing the risk of acute diverticulitis [26-30], and more 
recent evidences are available about the role of obesity on 
occurrence of DD complications [31, 32]. Overall consensus 
about these statement was very high, since all of them reached 
>80% agreement among respondents. 
2. Course of the disease
2.1 Symptomatic Uncomplicated Diverticular Disease 
(SUDD) is a distinct clinical syndrome characterized by 
recurrent abdominal symptoms attributed to diverticula in 
the absence of clinical, laboratory, or radiographic markers 
of overt inflammation. [EL: 1c; RG: B]
Consensus levels of agreement: A+ 49.19%; A 37.10%; A- 
11.29%; D- 0%; D: 1.61%; D+ 0.81%.
2.2 The pathophysiology is SUDD is poorly understood, 
with some evidence suggesting altered colonic motility, visceral 
hypersensitivity, microbiome alterations and/or subclinical 
inflammation playing etiological roles. [EL: 4; RG: D] 
Consensus levels of agreement: A+ 55.65%; A 30.65%; A- 
12.10%; D- 0.81%; D: 0.81%; D+ 0%.
2.3 There is no evidence to suggest that bowel habits 
or a change in those habits determine the evolution to 
diverticulitis. [EL: 1c; RG: B]
Consensus levels of agreement: A+ 48.49%; A 33.06%; A- 
12.90%; D- 4.03%; D: 0%; D+ 0.81%.
2.4 SUDD post-acute diverticulitis is a chronic 
inflammatory disease with prolonged chronic symptoms, high 
levels of systemic serum inflammatory markers, high levels 
of tissue inflammatory cytokine and chronic inflammatory 
infiltrates in the affected colonic tissue. [E: 2C; RG: B] 
Consensus levels of agreement: A+ 49.19%; A 18.55%; A- 
20.16%; D- 8.87%; D: 1.81%; D+ 1.81%.
 
2.5 There is still no definite evidence that rifaximin reduces 
acute episodes of diverticulitis. [EL: 4; RG: D]
Consensus levels of agreement: A+ 45.57%; A 39.52%; A- 
8.06%; D- 4.84%; D: 1.61%; D+ 0%.
2.6 There are some evidences that mesalazine could reduce 
symptoms following acute episode of diverticulitis. [EL: 3a; RG: B]
Consensus levels of agreement: A+ 17.74%; A 49.19%; A- 
28.23%; D- 1.61%; D: 1.61%; D+ 1.61%.
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2.7 At present, there is no evidence that mesalazine reduces 
acute episodes of diverticulitis. [EL: 1c; RG: B] 
Consensus levels of agreement: A+ 52.42%; A 28.23%; A- 
11.29%; D- 5.65%; D: 1.61%; D+ 0.81%.
Comments
These statements point out the new evidences about the 
evolution of diverticulosis towards occurrence of SUDD and 
acute diverticulitis. The first two statements define clearly that 
SUDD is a distinct clinical syndrome, with distinct clinical 
characteristics from irritable bowel syndrome (IBS) [33, 34], 
and have specific characteristics about cytokine expression and 
microbiota signature [24, 35-39]. The third statement clarify 
that, based on current evidences, changing of bowel habits do 
not seems to influence the evolution towards AD [40]. The forth 
statement points out patients experiencing SUDD following an 
episode of acute diverticulitis have persistence of inflammation 
in terms of  histological inflammation and increased expression 
of cytokines, findings that underscore the risk of AD recurrence 
[41, 42]. The last three statements point out that, at present, 
there are no clear evidences on how to prevent AD occurrence 
and its recurrence. Neither rifaximin nor mesalazine seems to 
be effective on both these topics [5, 43-44], while mesalazine 
seems to reduce symptoms following an episode of AD [45, 
46]. This because the trial design was not optimal, and this was 
particularly true for trials investigating mesalazine.  Also the 
overall consensus about these statement was very high, since 
all of them reached >80% agreement among respondents.
3. Diagnosis
3.1 No single biomarker is sensitive and specific enough 
to be recommended as diagnostic tool for symptomatic 
uncomplicated diverticular disease. [EL: 1a; GR: A]
Consensus levels of agreement: A+ 83.87%; A 15.32%; A- 
0%; D- 0%; D: 0.81%; D+ 0%.
 
3.2 C-reactive protein levels >150 mg/l strongly predicts 
complicated diverticulitis.  [EL: 1a; GR: A]
Consensus levels of agreement: A+ 43.55%; A 50%; A- 
6.45%; D- 0%; D: 0%; D+ 0%.
3.3 Faecal Calprotectin might be useful in distinguishing 
symptomatic uncomplicated diverticular disease from 
irritable bowel syndrome, but a cut-off level needs to be 
identified. [EL: 3c; GR: C]
Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 
8.87%; D- 0.81%; D: 2.42%; D+ 3.23%.
 
3.4 Contrast-enhanced computer tomography (CE-CT) 
should be considered as the first-line colonic examination since 
it offers a more comprehensive evaluation of uncomplicated 
and complicated forms; CE-CT can also be used to guide 
therapeutic interventions.  [EL 1b; GR: A]
Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 
8.87%; D- 0,81%; D: 2.42%; D+ 3.23%.
3.5 Ultrasound has slightly lower sensitivity and specificity 
compared to CT in the assessment of acute diverticulitis and 
its use as the first-line diagnostic procedure - followed by CT 
scan in the case of inconclusive sonographic findings - may 
spare the use of CT in more than 50% of cases.  [EL:  1a; GR: A]
Consensus levels of agreement: A+ 55.65%; A 23.39%; A- 
18.55%; D- 1.61%; D: 0.81%; D+ 0%.
3.6 Ultrasound coupled with i.v. contrast agents (CEUS) 
differentiates between peri-intestinal phlegmon and abscess 
and demonstrates the real extension of the abscess in acute 
diverticulitis. 
Ultrasound-guided drainage, when feasible, is the 
preferable option for abscesses larger than 3 cm. [EL: 4; GR: C]
Consensus levels of agreement: A+ 50%; A 41.13%; A- 0%; 
D- 0.81%; D: 0%; D+ 0%.
3.7 Ultrasound is useful to monitor the patients after 
the acute diverticulitis and in particular the lesions treated 
conservatively. [EL:  2b; GR: B]
Consensus levels of agreement: A+ 33.87%; A 48.39%; A- 
15.39%; D- 2.42%; D: 0%; D+ 0%.
3.8 Ultrasound may be of help in detecting symptomatic 
uncomplicated diverticular disease (SUDD) of the colon. 
[EL: 4; GR: C]
Consensus levels of agreement: A+ 27.42%; A 52.42%; A- 
13.71%; D- 3.23%; D: 1.61%; D+ 1.61%.
3.9 A prompt colonoscopy  (i.e. within 12–24 h) is 
mandatory for diagnosis and to direct therapy in diverticular 
bleeding. Massive bleeding should be managed with selective 
angiography. [EL: 2a; GR: B]
Consensus levels of agreement: A+ 45.97%; A 41.94%; A- 
6.45%; D- 5.65%; D: 0%; D+ 0%.
 
3.10. DICA endoscopic classification seems to have a 
predictive value on the outcome of the disease. EL: 1b; GR: B
Consensus levels of agreement: A+ 47.58%; A 45.97%; A- 
4.03%; D- 2.42%; D: 0%; D+ 0%.
Comments
These statements point out the new evidences about the 
role of diagnosis in diagnosing and managing SUDD and AD. 
The first three statements confirm the important predicting 
value of C-reactive protein (CRP) in define the presence 
and the severity of acute diverticulitis [47, 48], and that fecal 
calprotectin (FC) may be useful in differentiating between 
SUDD and IBS [35]. The forth statement confirms that the 
contrast-enhanced computer tomography is the gold standard 
to pose the diagnosis of AD and its complications [49]. The 
statements 3.5-3.8 underscore the increasing role of the 
intestinal ultrasound (IUS) in diagnosis both SUDD and AD, 
underscoring also the limit of this technique, namely that it 
operator-sensitive [50-52]. The statement 3.9 points out the role 
of colonoscopy in those people. In particular, it underscore the 
role of colonoscopy in managing diverticular bleeding, which is 
the main cause of lower gastrointestinal bleeding and linked to 
the advanced age and the numerous, associated comorbidities 
[53-55]. The last statement point out the attention on the 
first validated endoscopic classification on diverticulosis and 
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diverticular disease, called DICA (Diverticular Inflammation 
and Complication Assessment) [55]. This classification, very 
easy to use, has a significant predicting value on the outcome 
of the disease (57), and has also a significant interobserver 
agreement in real life [58].  The overall consensus about these 
statement was very high, since all of them reached >80% 
agreement among respondents.
4. Medical treatment
4.1 Rifaximin plus fibre is effective in reducing symptoms 
in SUDD patients compared to fibre alone. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 66.94%; A 28.23%; A- 
3.23%; D- 1.61%; D: 0%; D+ 0%.
4.2 Mesalazine is effective in reducing symptoms in SUDD 
patients.  [EL: 1b; GR: A]
Consensus levels of agreement: A+51.61%; A 34.68%; A- 
11.29%; D- 1.61%; D: 0.81%; D+ 0%.
4.3 There are some evidences that probiotics could be 
effective in reducing symptoms in SUDD patients [EL: 3a; 
GR: B]
Consensus levels of agreement: A+32.26%; A 36.29%; A- 
28.23%; D- 3.23%; D: 0%; D+ 0.81%.
Comments
These statements focused their attention just on the treatment 
of SUDD, which is still under active debate. In particular, 
focusing their attention on the efficacy of non-absorbable 
antibiotics (namely rifaximin), anti-inflammatory drugs (namely 
mesalazine), and probiotics. The first statement confirms that 
rifaximin, especially when associated with fibre, is effecting in 
reducing symptoms in SUDD [43, 59]. The second statement 
claims that mesalazine is also effective in reducing symptoms in 
those people and in preventing its recurrence during the follow-
up [46, 60, 61]. The last statement claims that there are some 
interesting news in using probiotics in those people [61, 62], but 
data are still too heterogeneous to drawn any definite conclusions. 
It is noteworthy the impressive overall consensus about these 
statement, reaching >90% agreement among respondents.
5. Surgical treatment
5.1 Treatment of acute uncomplicated diverticulitis (AUD) 
without antibiotics is safe and effective and it is not associated 
with worse outcomes, including need for surgery, complications, 
recurrence and lenght of hospital stay. [EL: 2b; GR: B]
Consensus levels of agreement: A+28.23%; A 41.94%; A- 
13.71%; D- 8.87%; D: 3.23%; D+ 4.03%.
5.2 In Uncomplicated Acute Diverticulitis antibiotic therapy 
is still considered in patients immunocompromised, with severe 
comorbidities (ASA>2) and with sign of sepsis. [EL: 3b; GR: C]
Consensus levels of agreement: A+79.03%; A 20.97%; A- 
0%; D- 0%; D: 0%; D+ 0%.
5.3 There are some evidence that high CPR level (>170 
mg/ml) or a initial CT  findings of  fluid collection and 
longer inflamed colon could be useful factors in selecting 
patients who could benefit of  antibiotic treatment, but these 
preliminary data need to be confirmed by further studies. 
[EL: 4; GR: C]
Consensus levels of agreement: A+69.35%; A 28.23%; A- 
2.42%; D- 0%; D: 0%; D+ 0%.
5.4 The open approach to acute diverticulitis in urgent/
emergent setting should be preferred for patients with 
hemodynamic instability, or when an adequate expertise in 
colorectal laparoscopy is not available. [EL: 4; GR: B]
Consensus levels of agreement: A+82.26%; A 14.52%; A- 
3.23%; D- 0%; D: 0%; D+ 0%.
5.5 Laparoscopic resection is safe and provides faster 
recovery in uncomplicated cases: cases; it has to be performed 
by well-trained surgeons. [EL: 2b; GR: B]
Consensus levels of agreement: A+77.42%; A 20.97%; A- 
1.61%; D- 0%; D: 0%; D+ 0%.
5.6 Laparoscopic peritoneal lavage may be an alternative 
to manage purulent peritonitis Hinchey III in diverticular 
disease. [EL: 4; GR: B]
Consensus levels of agreement: A+19.35%; A 50%; A- 
16.94%; D- 8.87%; D: 4.84%; D+ 0%.
5.7 The decision to perform elective resection after one or 
more episodes of AD should be undertaken on a “case-by-case” 
basis. [EL: 2b; GR: B]
Consensus levels of agreement: A+71.77%; A 25%; A- 
3.23%; D- 0%; D: 0%; D+ 0%.
Comments
These statements focused their attention mainly on the 
surgical treatment of treatment of AD, since SUDD has not a 
surgical recommendation. The first statements are dedicated to 
the current indication on antibiotic of in the setting of AD. The 
first claims that the management of acute diverticulitis without 
antibiotics does not increase these worse outcomes [63-68]. 
Therefore, the second statement confirms that antibiotics 
have to be used by a “case-by-case” basis [5, 66], and that 
some parameters (namely levels of PCR and CT findings at 
entry) may be predictive on the need to use antibiotics in this 
population (48,66). The last three statement confirms that the 
open or the laparoscopic approach to AD, as well as an elective 
resection after multiple episode of AD have to follow a “case-
by-case” basis [69, 73]. It is noteworthy the impressive overall 
consensus about these statements, since disagreement on them 
among respondents was almost absent.
6. Critical issues
6.1 Ambulatory treatment of uncomplicated acute 
diverticulitis is safe, effective and applicable to patients who 
do not present concomitant unstable comorbid conditions; 
immunosuppression; cognitive, social, or psychiatric 
impairment; and intolerance to oral intake.
Outpatient management allows important cost saving to 
the health systems without negative influence on the quality 
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of life of patients with uncomplicated diverticulitis. [EL: 1a; 
GR: A]
Consensus levels of agreement: A+60.48%; A 36.29%; A- 
3.23%; D- 0%; D: 0%; D+ 0%.
6.2 Segmental Colitis Associated with Diverticulosis 
(SCAD) is a chronic inflammation occurring in the colon 
harboring diverticulosis that seems to resemble a chronic 
inflammatory disease rather than a complicated diverticular 
disease.
Treatment options include antibiotics (Ciproxin and 
metronidazole), 5-ASA and probiotics for mild cases. In severe 
disease the use of systemic steroids might be warranted. Anti 
TNFα treatment may be beneficial in severe disease resistant 
to other therapeutic options. Treatment duration might vary 
depending on clinical response and can last weeks-months. 
[EL: 2b; GR: C].
Consensus levels of agreement: A+48.39%; A 41.13%; A- 
8.87%; D- 0%; D: 0%; D+ 0%.
6.3 Diverticular inflammation is not a causative risk 
factor for colorectal cancer (CRC) but is an important factor 
that should be taken into account requiring early colonoscopy 
to exclude cancer.  [EL: 2a; GR: B].
Consensus levels of agreement: A+73.39%; A 22.58%; A- 
4.03%; D- 0%; D: 0%; D+ 0%.
Comments
These statements focused their attention on three topics 
under active debate. The first statement claims about the safety 
of ambulatory treatment of uncomplicated AD, which is safe 
and  effective [73-79]. Moreover, this approach has also a 
significant impact on cost-saving [79]. The second statement 
claims that segmental colitis associated with diverticulosis 
(SCAD), is a chronic disease occurring in a colon harbouring 
diverticulosis, and that seems to be a chronic inflammatory 
bowel disease than a complication of DD [80-83]. This disease 
may be treated with a variety of treatments, from antibiotic and 
5-ASA to anti-TNFα antibodies [84, 85]. The last statement 
confirms that DD is not a causative risk factor for colorectal 
cancer (CRC) [86, 87]. However, it should be excluded in 
patients after an episode of complicated acute diverticulitis, 
especially when the colon has not been studied never before 
[88]. It is noteworthy the impressive overall consensus about 
these statements, since any disagreement was recorded among 
respondents.
CONCLUSIONS
These guidelines represent a consensus of best practice 
based on the available evidence as showed at the time of the 
3rd International Symposium on Diverticular Disease. The 
statement proposed and voted during this Symposium have 
been developed starting from the statements voted during 
the 2nd International Symposium on Diverticular Disease, 
held in Rome on April 2016 [5], and have been conceived as 
an improvement of the points in which there were no clear 
evidence at that time. This is because these guidelines are 
not described in a classical way (“epidemiology”, “diagnosis”, 
“treatment”, etc,), as well as no every finding of the disease has 
been voted or discussed. On the contrary, the sessions (and 
the statements, as consequence) have been designed just as 
improvement of that it is already clearly known. The strength 
of these guidelines is that the statements have been designed 
by several International experts using a Delphi-like process, 
and have been approved by a large population of physicians, 
involving all medical categories managing DD, and coming 
from European, Northern and Southern America, Australian 
and African countries.  
They may not apply to all situations and should be 
interpreted in the light of specific clinical situations and 
resource availability. Further controlled clinical studies may 
be needed to clarify some aspects of these statements, and 
revision will definitely be needed, as new data will become 
available. This is particularly true not only for some medical 
treatments currently under active debate (in example, how 
to prevent acute diverticulitis recurrence), but also for some 
surgical aspects (example when to operate DD).
These Guidelines are not rules, but are intended to be an 
educational tool to provide information that may assist each 
medical category (general practitioners, gastroenterologists and 
surgeons) in providing care to patients, not as encouraging, 
advocating, requiring, or discouraging any particular treatment.
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